Outside the Trial's Population
A disease-modifying ALS therapy's pivotal trial enrolled patients earlier in disease and with stronger lung function than this patient has now. What that mismatch should mean for the conversation, and what actually helps him today, are separable questions.
F.T. taught high school history for thirty-two years before retiring, and still keeps a shelf of student thank-you notes he says he reads on hard days — of which there have been more lately. He was diagnosed with ALS fourteen months ago after a year of progressively worsening hand weakness that started, unremarkably, as trouble gripping chalk. He has been on riluzole since diagnosis. What brought today's family meeting wasn't a new symptom so much as a new number: his forced vital capacity, tracked every clinic visit, has fallen from 68% predicted six months ago to 52% now — a real, measurable acceleration his neurologist flagged directly rather than downplaying. His wife and daughter, present at the visit, raised edaravone, a disease-modifying therapy neither he nor his prior clinic had discussed in detail.
The honest answer requires being specific about what edaravone's evidence actually covers. Its pivotal trial — Study 19, published by the Edaravone ALS 19 Study Group in 2017 — enrolled only patients with a forced vital capacity of at least 80% predicted, within two years of symptom onset, and scoring at least 2 on every ALSFRS-R item. F.T. fails the first criterion outright at 52%, and fails the second as well once the clock is started where the trial started it: a year of hand weakness preceded his diagnosis fourteen months ago, putting him past two years from onset. The enrollment was narrow enough that fewer than one screened patient in ten qualified. That mismatch doesn't mean the drug cannot work in more advanced disease — a post-hoc analysis of Study 19's own lower-FVC subgroup found reduced ALSFRS-R decline — but post-hoc is the operative word, and the modest effect size seen in the earlier, healthier population may not transfer proportionally, or at all, to his current stage. Separate from that question, and not contingent on how it resolves, is his sialorrhea, which has become a real, present-tense problem affecting his ability to read aloud to his granddaughter. It is treatable today — though not quite as freely as it would be in a patient with a stronger cough, since an anticholinergic that dries saliva thickens bronchial secretions too, and at an FVC of 52% clearing them is already work. His riluzole, unlike edaravone, was never in question at this visit; the dose-ranging trials that established its survival benefit enrolled across a wider FVC range than Study 19 permitted, and nothing in his recent decline changes that calculation.
ALS multidisciplinary family meeting
I want to be honest about what edaravone's evidence actually covers. The pivotal trial enrolled patients with FVC at 80% or above and early-stage disease. His FVC is 52% now, and it's falling — he's well outside that population. That doesn't prove the drug can't help him at all, but it does mean we don't have direct evidence it does, at a stage this advanced, and I don't want to imply a magnitude of benefit the trial never actually showed for someone in his situation.
I hear that, and I think it's important they hear it plainly too. But ALS doesn't have a point where trial-matching becomes the only thing that decides treatment — it's relentlessly progressive at every stage, and if there's a real, approved option that plausibly slows that even modestly, the family's wish to try it is a legitimate part of this decision, not something the evidence gap should simply override on its own.
I'm not disputing the trial-population mismatch — I'm saying that gap is information for the family's decision, not a decision made for them; what matters is that they understand the realistic, modest size of even the in-trial benefit before choosing, not that the option gets closed off because he doesn't match the original enrollment criteria.
Whatever the family decides about edaravone, I don't want that conversation to crowd out something simpler that's already sitting in front of us. His sialorrhea is affecting real, day-to-day moments for him — reading to his granddaughter, by his own account. That's a well-established problem to treat — with the caveat that drying his saliva thickens what is left in his airways, and at an FVC of 52% he has less cough to clear it with, so we start low and watch. It doesn't need to wait on a harder decision being resolved first. Let's start there today, regardless of where the edaravone conversation lands.
Agreed, without contest: glycopyrrolate starts today for sialorrhea, with a follow-up call in two weeks to assess effect and tolerability; riluzole continues unchanged.
Not agreed, and explicitly left open rather than decided by the clinical team: whether to start edaravone. The neurologist's honest read is that the evidence does not clearly support meaningful benefit at his current disease stage; the palliative care specialist believes the family's informed wish to try it, after full and honest discussion of realistic expected benefit, should carry real weight regardless. Both agreed the decision belongs to F.T. and his family after that fuller discussion, scheduled for a dedicated follow-up visit rather than decided today under time pressure.